Wednesday 02 Sep 2015

Stocks With New Trends Developing: Strikeforce Technologies Inc (OTCMKTS:SFOR), AMARANTUS BIOSCIENCE HOLDINGS, INC. (OTCBB:AMBS)

New York, NY – (NISMAGAZINE) –08/30/2013- Strikeforce Technologies Inc (OTCMKTS:SFOR) fell 21.74% at $0.0018 after trading 210.32 million shares, much higher than its normal average daily volume of 42.50 million shares. The stock rose higher yesterday but made an about-turn from the region of the 200-day moving average, and closed below the open, in the process creating a bearish shooting star pattern. The move followed a massive jump in the previous session following news that the company had been granted a patent by the USPTO for its Keystroke Encryption technology. For the quarter ended June 30, 2013, SFOR reported revenue of $27K and a net loss of $669K.

Is SFOR a solid investment at these levels? Get valuable insight and must-know updates here.

AMARANTUS BIOSCIENCE HOLDINGS, INC. (OTCBB:AMBS) gained 34.09% at $0.059 after trading 13.92 million shares. On Tuesday the company announced the publication of two new independent peer-reviewed publications on its patented biologic MANF. “This year has been a pivotal year for MANF in terms of gaining widespread recognition in the international scientific community as a molecule of great interest in the cellular response involving the endoplasmic reticulum that protects against protein misfolding and aggregation, processes centrally involved in a wide number of diseases,” said Gerald E. Commissiong, President & CEO of Amarantus. It is a development-stage biotechnology company with a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Alzheimer’s disease, Traumatic Brain Injury, and other human diseases. Last week, the company announced it had concluded an equity financing arrangement with Dominion Capital whereby about $1.2M of accounts payable would be exchanged for Series D Preferred Shares of the company. Earlier this month the company announced positive data for MANF in the degenerative disease known as Retinitis Pigmentosa, which is an orphan disease under FDA regulations. On the daily chart the stock has broken out of a 3-month old rectangle consolidation pattern with rising volumes. It has crossed above the 50-week moving average as well as the 200-day moving average. The stock looks highly bullish.

How Should Investors Trade AMBS Now? Check out this exclusive report!


Subscribe for FREE to receive our “50 Stock Trading Rules No Hedge Fund Wants You To Know!” E-Book: continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.


Gale Wills


Leave a Comment